Theratechnologies Anno IPO
Cos'è Anno IPO di Theratechnologies?
Anno IPO di Theratechnologies, Inc. è 1996
Qual è la definizione di Anno IPO?
L'offerta pubblica iniziale è un tipo di offerta pubblica in cui le azioni di una società di solito sono vendute a investitori istituzionali che, a loro volta, vendono al pubblico in generale, su una borsa valori, per la prima volta.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Anno IPO di aziende nel Health Care settore su TSX rispetto a Theratechnologies
Cosa fa Theratechnologies?
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Aziende con anno ipo simili a Theratechnologies
- Shaw Communications ha Anno IPO di 1995
- Husky ha Anno IPO di 1995
- Transcontinental , Cl B Mv ha Anno IPO di 1995
- Mountain Inc ha Anno IPO di 1995
- Brookfield Asset Management ha Anno IPO di 1995
- ShawCor ha Anno IPO di 1995
- Theratechnologies ha Anno IPO di 1996
- BXP ha Anno IPO di 1997
- Faro Technologies ha Anno IPO di 1997
- Silgan ha Anno IPO di 1997
- Warrior Gold ha Anno IPO di 1997
- Ryanair Plc ha Anno IPO di 1997
- SIGA Technologies Inc ha Anno IPO di 1997